Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX vs 5-FU/LV in Adjuvant Colon Cancer
NCT00069121Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2003
- Primary completion
- Apr 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of capecitabine in colon carcinoma, sponsored by Roche. Started Apr 2003; status: completed.
02
Drugs
capecitabine
03
Conditions
colon carcinoma
Beyond the preview
Go deeper on NCT00069121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069121.